Navigation Links
Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
Date:8/25/2010

ALISO VIEJO, Calif., Aug. 25 /PRNewswire/ -- Ambry Genetics, a global leader in genomic services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of Illumina systems since late 2007 and has extensive experience as a Certified Service Provider. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing.  Ambry has gained a solid reputation for quality data and service as well as flexibility in customizing projects to meet the specific needs of researchers.  

(Logo:  http://photos.prnewswire.com/prnh/20090428/LA06744LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

The addition of the HiSeq 2000 will allow Ambry Genetics to run large projects for its customers while saving costs and providing the fastest turn-around times for sequencing. Ambry Genetics has an experienced bioinformatics team that can generate custom reports, providing flexible and results-driven informatics for sequencing projects. In addition to sequencing, Ambry Genetics currently offers diverse options for researchers interested in sequence capture / target enrichment by utilizing Agilent Technologies SureSelect, RainDance Technologies and Roche Nimblegen.

The new Illumina BeadXpress adds high-throughput genotyping capabilities to Ambry Genetics' existing line of services. The BeadXpress uses GoldenGate assays on the VeraCode technology which provides researchers with accuracy, flexibility and scalability for their projects.  The system supports high level variant plexing and can process up to 96 samples per plate, which can dramatically reduce the cost of genotyping assays and deliver rapid turn-around times.

About Ambry Genetics -Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com


'/>"/>
SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
2. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
3. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
4. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Genetics Determine Optimal Drug Dose of Common Anticoagulant
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
10. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
11. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/19/2017)... (PRWEB) , ... January 20, 2017 , ... Today, the ... to participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who ... patients. APMs are an important part of the Administration’s effort to build a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
Breaking Medicine News(10 mins):